{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T13:52:38Z","timestamp":1762005158752,"version":"3.41.2"},"reference-count":42,"publisher":"American Society for Microbiology","issue":"5","license":[{"start":{"date-parts":[[2020,4,21]],"date-time":"2020-04-21T00:00:00Z","timestamp":1587427200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2020,4,21]]},"abstract":"<jats:p>\n            Nosocomial pneumonia (NP), including ventilator-associated pneumonia (VAP), is increasingly associated with multidrug-resistant Gram-negative pathogens. This study describes the\n            <jats:italic>in vitro<\/jats:italic>\n            activity of ceftazidime-avibactam, ceftazidime, and relevant comparator agents against bacterial pathogens isolated from patients with NP, including VAP, enrolled in a ceftazidime-avibactam phase 3 trial. Gram-positive pathogens were included if coisolated with a Gram-negative pathogen.\n            <jats:italic>In vitro<\/jats:italic>\n            susceptibility was determined at a central laboratory using Clinical and Laboratory Standards Institute broth microdilution methods.\n          <\/jats:p>","DOI":"10.1128\/aac.02356-19","type":"journal-article","created":{"date-parts":[[2020,2,17]],"date-time":"2020-02-17T13:15:01Z","timestamp":1581945301000},"update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":9,"title":["<i>In Vitro<\/i>\n            Activity of Ceftazidime-Avibactam against Isolates from Respiratory and Blood Specimens from Patients with Nosocomial Pneumonia, Including Ventilator-Associated Pneumonia, in a Phase 3 Clinical Trial"],"prefix":"10.1128","volume":"64","author":[{"given":"Gregory G.","family":"Stone","sequence":"first","affiliation":[{"name":"Pfizer, Groton, Connecticut, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patricia A.","family":"Bradford","sequence":"additional","affiliation":[{"name":"AstraZeneca Pharmaceuticals, Waltham, Massachusetts, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Margaret","family":"Tawadrous","sequence":"additional","affiliation":[{"name":"Pfizer, Groton, Connecticut, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dianna","family":"Taylor","sequence":"additional","affiliation":[{"name":"TaylorMade Health, Ltd, Warrington, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mary Jane","family":"Cadatal","sequence":"additional","affiliation":[{"name":"Pfizer, Manila, Philippines"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhangjing","family":"Chen","sequence":"additional","affiliation":[{"name":"AstraZeneca, Shanghai, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph W.","family":"Chow","sequence":"additional","affiliation":[{"name":"Pfizer, Collegeville, Pennsylvania, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"crossref","first-page":"20316","DOI":"10.2807\/ese.17.46.20316-en","article-title":"The European Centre for Disease Prevention and Control (ECDC) pilot point prevalence survey of healthcare-associated infections and antimicrobial use","volume":"17","author":"Zarb P","year":"2012","unstructured":"Zarb P, Coignard B, Griskeviciene J, Muller A, Vankerckhoven V, Weist K, Goossens M, Vaerenberg S, Hopkins S, Catry B, Monnet D, Goossens H, Suetens C. 2012. The European Centre for Disease Prevention and Control (ECDC) pilot point prevalence survey of healthcare-associated infections and antimicrobial use. Euro Surveill 17:20316.","journal-title":"Euro Surveill"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciw353"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1086\/664048"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1306801"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMsa1300991"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1086\/653053"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(17)30747-8"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.06.00049105"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02252-12"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.00036-08"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12941-014-0043-3"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13613-015-0061-0"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1378\/chest.14-2171"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkw239"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.2147\/CE.S40698"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-013-0013-7"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00568-10"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1205073109"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciw378"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2017.01.010"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciw133"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(16)30004-4"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dks523"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1185\/03007995.2012.748653"},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofz149"},{"key":"e_1_3_2_27_2","volume-title":"AVYCAZ (ceftazidime and avibactam) for injection, for intravenous use","author":"Allergan","year":"2019","unstructured":"Allergan. 2019. AVYCAZ (ceftazidime and avibactam) for injection, for intravenous use. Allergan, Irvine, CA. https:\/\/www.allergan.com\/assets\/pdf\/avycaz_pi."},{"key":"e_1_3_2_28_2","unstructured":"Pfizer. 2019. Summary of product characteristics: Zavicefta 2 g\/0.5 g powder for concentrate for solution for infusion. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/004027\/WC500210234.pdf."},{"key":"e_1_3_2_29_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10096-016-2703-z"},{"key":"e_1_3_2_30_2","doi-asserted-by":"publisher","DOI":"10.1186\/cc13775"},{"key":"e_1_3_2_31_2","volume-title":"Performance standards for antimicrobial susceptibility testing: 22nd informational supplement M100-S22","author":"Clinical and Laboratory Standards Institute","year":"2012","unstructured":"Clinical and Laboratory Standards Institute. 2012. Performance standards for antimicrobial susceptibility testing: 22nd informational supplement M100-S22. CLSI, Wayne, PA."},{"key":"e_1_3_2_32_2","unstructured":"Mendes RE Castanheira M Woosley LN Doyle T Stone G Mclaughlin R Bradford P Flamm R. 2017. Beta-lactamase characterization of baseline Gram-negative pathogens from a phase 3 trial of ceftazidime-avibactam (CAZ-AVI) for the treatment of nosocomial pneumonia abstr P0408. Twenty-seventh ECCMID Vienna Austria."},{"key":"e_1_3_2_33_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00756-10"},{"key":"e_1_3_2_34_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01820-16"},{"key":"e_1_3_2_35_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkw561"},{"key":"e_1_3_2_36_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02584-17"},{"key":"e_1_3_2_37_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01045-17"},{"key":"e_1_3_2_38_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00220-16"},{"key":"e_1_3_2_39_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02286-15"},{"key":"e_1_3_2_40_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkq306"},{"key":"e_1_3_2_41_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00223-18"},{"key":"e_1_3_2_42_2","unstructured":"Pfizer. 2016. TYGACIL (tigecycline) for injection for intravenous use: prescribing information. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2016\/021821s039lbl.pdf."},{"key":"e_1_3_2_43_2","volume-title":"Performance standards for antimicrobial susceptibility testing: 28th informational supplement M100-S28","author":"Clinical and Laboratory Standards Institute","year":"2018","unstructured":"Clinical and Laboratory Standards Institute. 2018. Performance standards for antimicrobial susceptibility testing: 28th informational supplement M100-S28. CLSI, Wayne, PA."}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.02356-19","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.02356-19","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T21:45:00Z","timestamp":1645479900000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.02356-19"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,21]]},"references-count":42,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2020,4,21]]}},"alternative-id":["10.1128\/AAC.02356-19"],"URL":"https:\/\/doi.org\/10.1128\/aac.02356-19","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"type":"print","value":"0066-4804"},{"type":"electronic","value":"1098-6596"}],"subject":[],"published":{"date-parts":[[2020,4,21]]},"assertion":[{"value":"2019-11-26","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-02-12","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-04-21","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e02356-19"}}